Increased expression of protease-activated receptor 1 (PAR-1) in human leukemias

被引:17
作者
Veiga, Camilla de S. B.
Carneiro-Lobo, Tatiana C.
Coelho, Claudia J. B. P. [2 ]
Carvalho, Silvia M. F. [2 ]
Maia, Raquel C. [3 ]
Vasconcelos, Flavia C. [3 ]
Abdelhay, Eliana [4 ]
Mencalha, Andre L. [4 ]
Ferreira, Aline F. [5 ]
Castro, Fabiola A. [5 ]
Monteiro, Robson Q. [1 ]
机构
[1] Univ Fed Rio de Janeiro, CCS, Inst Bioquim Med, Ilha Fundao, BR-21941590 Rio De Janeiro, Brazil
[2] Inst Estadual Hematol Arthur Siqueira Cavalcanti, Lab Serv, Rio De Janeiro, Brazil
[3] INCa, CGTC, Programa Pesquisa Hematooncol Mol, Rio De Janeiro, Brazil
[4] INCa, Lab Celulas Tronco, Rio De Janeiro, Brazil
[5] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, Ribeirao Preto, SP, Brazil
关键词
Protease-activated receptor 1 (PAR-1); Thrombin; Acute myeloid leukemia; Chronic myeloid leukemia; ACUTE PROMYELOCYTIC LEUKEMIA; TISSUE FACTOR; SURVIVAL FACTOR; CANCER-CELLS; THROMBIN; ANGIOGENESIS; COAGULATION; PATHWAYS; MOTILITY; INVASION;
D O I
10.1016/j.bcmd.2010.12.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Protease-activated receptor 1 (PAR-1) is a G-protein-coupled receptor that is overexpressed in solid tumors, being associated with several pro-tumoral responses including primary growth, invasion, metastasis and angiogenesis. Expression of PAR-1 in human leukemic cell lines is reported but the status of its expression in human leukemic patients is currently unknown. In this study we evaluated the expression pattern of PAR-1 in patients with the four main types of leukemia - chronic lymphocytic leukemia subtype B (B-CLL), acute lymphoblastic leukemia subtype B (B-ALL), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Flow cytometry analyses show that lymphocytes from B-CLL patients express this receptor at similar levels to healthy individuals. On the other hand, it was observed a significant increase in PAR-1 expression in B-ALL lymphocytes as compared to B-CLL and healthy donors. Flow cytometric and real-time PCR demonstrated a significant increase in PAR-1 expression in granulocytes from CML patients in blast phase (CML-BP) but not in chronic phase (CML-CP) as compared to healthy donors. Finally, a significant increase in PAR-1 expression has been also observed in blasts from AML (subtypes M4 and M5) patients, as compared to monocytes or granulocytes from healthy donors. We conclude that PAR-1 might play an important biological role in aggressive leukemias and might offer additional strategies for the development of new therapies. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:230 / 234
页数:5
相关论文
共 50 条
  • [31] Role of Matrix Metalloproteinase-1(MMP-1)/Protease-activated Receptor-1(PAR-1) Signaling Pathway in the Cervical Cancer Invasion
    Ning-xia SUN
    Qian ZHAO
    Chen YE
    Yan MA
    Wen LI
    Journal of Reproduction and Contraception, 2014, (01) : 18 - 25
  • [32] Coagulation-Driven Hepatic Fibrosis Requires Protease Activated Receptor-1 (PAR-1) in a Mouse Model of TCDD-Elicited Steatohepatitis
    Nault, Rance
    Fader, Kelly A.
    Kopec, Anna K.
    Harkema, Jack R.
    Zacharewski, Timothy R.
    Luyendyk, James P.
    TOXICOLOGICAL SCIENCES, 2016, 154 (02) : 381 - 391
  • [33] Protease-activated receptor type 1 (PAR1) increases CEMP1 gene expression through MAPK/ERK pathway
    Rovai, Emanuel Silva
    Alves, Tomaz
    Gasparoni, Leticia Miquelitto
    de Franca, Bruno Nunes
    Sipert, Carla Renata
    Kantarci, Alpdogan
    Holzhausen, Marinella
    BRAZILIAN ORAL RESEARCH, 2022, 36
  • [34] Protease-activated receptor 1 (PAR1) signalling desensitization is counteracted via PAR4 signalling in human platelets
    Falker, Knut
    Haglund, Linda
    Gunnarsson, Peter
    Nylander, Martina
    Lindahl, Tomas L.
    Grenegard, Magnus
    BIOCHEMICAL JOURNAL, 2011, 436 : 469 - 480
  • [35] Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19
    Tran, Florian
    Harris, Danielle M. M.
    Scharmacher, Alena
    Grasshoff, Hanna
    Sterner, Kristina
    Schinke, Susanne
    Kading, Nadja
    Humrich, Jens Y.
    Cabral-Marques, Otavio
    Bernardes, Joana P.
    Mishra, Neha
    Bahmer, Thomas
    Franzenburg, Jeanette
    Hoyer, Bimba F.
    Gluck, Andreas
    Guggeis, Martina
    Ossysek, Alexander
    Kuller, Andre
    Frank, Derk
    Lange, Christoph
    Rupp, Jan
    Heyckendorf, Jan
    Gaede, Karoline I.
    Amital, Howard
    Rosenstiel, Philip
    Shoenfeld, Yehuda
    Halpert, Gilad
    Rosenberg, Avi Z.
    Schulze-Forster, Kai
    Heidecke, Harald
    Riemekasten, Gabriela
    Schreiber, Stefan
    ERJ OPEN RESEARCH, 2022, 8 (04)
  • [36] Focal ischemia induces expression of protease-activated receptor1 (PAR1) and PAR3 on microglia and enhances PAR4 labeling in the penumbra
    Henrich-Noack, P
    Riek-Burchardt, M
    Baldauf, K
    Reiser, G
    Reymann, KG
    BRAIN RESEARCH, 2006, 1070 (01) : 232 - 241
  • [37] Protease-activated Receptor 1 (PAR1) and PAR4 Heterodimers Are Required for PAR1-enhanced Cleavage of PAR4 by α-Thrombin
    Arachiche, Amal
    Mumaw, Michele M.
    de la Fuente, Maria
    Nieman, Marvin T.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (45) : 32553 - 32562
  • [38] Protease-Activated Receptor-1 Antagonists: Focus on SCH 530348
    Sugunaraj, Jaya Prakash
    Mehta, Vimal
    Kalra, Ankur
    Sukhija, Rishi
    Palaniswamy, Chandrasekar
    AMERICAN JOURNAL OF THERAPEUTICS, 2012, 19 (06) : 465 - 469
  • [39] Protease-activated receptor-1 (PAR1) and PAR2 but not PAR4 mediate relaxations in lower esophageal sphincter
    Huang, Shih-Che
    REGULATORY PEPTIDES, 2007, 142 (1-2) : 37 - 43
  • [40] Protease-activated receptor-1-mediated DNA synthesis in cardiac fibroblast is via epidermal growth factor receptor transactivation - Distinct PAR-1 signaling pathways in cardiac fibroblasts and cardiomyocytes
    Sabri, A
    Short, J
    Guo, JF
    Steinberg, SF
    CIRCULATION RESEARCH, 2002, 91 (06) : 532 - 539